EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinieOpen Access · CC BY-NC 4.0

Progestogen therapy in threatened miscarriage and unexplained recurrent pregnancy loss: Recommendations by the Thai interest group

Kiattisak Kongwattanakul iD, Phudit Jatavan, Olarik Musigavong, Savitree Pranpanus, Lingling Salang iD, Chonthicha Satirapod, Somsin Petyim, Boonchai Uerpairojkit iD

Journal of Obstetrics and Gynaecology Research · 2025

DOI: 10.1111/jog.70038 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2025. Verfasst von Kiattisak Kongwattanakul und 7 weiteren Autor:innen. Beteiligte Einrichtung: Maternal Fetal Medicine Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. Hauptthemen laut MEDLINE: Abortion, Habitual, Progestins, Abortion, Threatened, Progesterone. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Abbott Laboratories Ltd., Bangkok, Thailand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Threatened miscarriage and unexplained recurrent pregnancy loss (RPL) pose significant physical and psychological challenges for women and their families globally. The lack of local guidelines and variations in recommendations by existing guidelines result in inconsistent management of these conditions in Thailand. The Thai interest group aims to provide recommendations to healthcare providers for the use of progesterone supplementation in women experiencing threatened miscarriage and unexplained RPL.

Methods

Existing guidelines and relevant studies were reviewed to explore the role of oral, vaginal, and injectable progestogens. In the present evidence‐based recommendations, the Thai interest group delineated effective diagnostic and therapeutic strategies for managing patients with threatened miscarriages and unexplained RPL.

Results

Treatment initiation for unexplained RPL is recommended after experiencing two or more pregnancy losses, regardless of consecutive occurrences. Oral progestogen (dydrogesterone) is recommended for the management of both threatened miscarriage and unexplained RPL. Exceeding 200 mg of micronized vaginal progesterone (MVP) per intake is not advisable for threatened miscarriage or preventing recurrent miscarriage because of luteal phase insufficiency. Treatment with intramuscular injection progestin should be continued at a dosage of 250 mg twice weekly for several weeks. Additionally, patient experiences and safety concerns related to MVP and injectable progestogens are discussed.

Conclusion

These inaugural evidence‐based Thai recommendations can be applied in regional healthcare settings for improved outcomes in threatened miscarriage and unexplained RPL. Further research is needed to better understand the epidemiology and etiology of these conditions in Thailand.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abortion, HabitualProgestinsAbortion, ThreatenedProgesteroneHumansFemalePregnancyThailandDydrogesteroneSoutheast Asian People

Stichwörter der Autor:innen

progesteroneprogestogenrecommendationsrecurrent pregnancy lossthreatened miscarriage

Substanzen

ProgestinsProgesteroneDydrogesterone

Autor:innen und Institutionen

  • Maternal Fetal Medicine Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Maternal and Fetal Medicine Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Thailand.
  • Chaophya Abhaibhubejhr Hospital, Prachinburi, Thailand.
  • Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand.
  • Reproductive Medicine Unit, Obstetrics and Gynecology Department, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Reproductive Endocrinology and Infertility Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

ORCID-Profile: Kiattisak Kongwattanakul, Lingling Salang, Boonchai Uerpairojkit

Förderung

  • Abbott Laboratories Ltd., Bangkok, Thailand

Zitieren

APA

Kongwattanakul, K., Jatavan, P., Musigavong, O., Pranpanus, S., Salang, L., Satirapod, C., Petyim, S., & Uerpairojkit, B. (2025). Progestogen therapy in threatened miscarriage and unexplained recurrent pregnancy loss: Recommendations by the Thai interest group. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.70038

Vancouver

Kongwattanakul K, Jatavan P, Musigavong O, Pranpanus S, Salang L, Satirapod C, et al. Progestogen therapy in threatened miscarriage and unexplained recurrent pregnancy loss: Recommendations by the Thai interest group. Journal of Obstetrics and Gynaecology Research. 2025. doi:10.1111/jog.70038

BibTeX
@article{Kongwattanakul2025,
  author = {Kongwattanakul, Kiattisak and Jatavan, Phudit and Musigavong, Olarik and Pranpanus, Savitree and Salang, Lingling and Satirapod, Chonthicha and Petyim, Somsin and Uerpairojkit, Boonchai},
  title = {Progestogen therapy in threatened miscarriage and unexplained recurrent pregnancy loss: Recommendations by the Thai interest group},
  journal = {Journal of Obstetrics and Gynaecology Research},
  year = {2025},
  doi = {10.1111/jog.70038}
}
Kostenlos starten →